Zero Treated Bleeds Data
See the HEMLIBRA zero treated bleeds data for patients with and without FVIII inhibitors
See the HEMLIBRA zero treated bleeds data for patients with and without FVIII inhibitors
HEMLIBRA® is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
Boxed WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Warnings and Precautions
Thrombotic Microangiopathy (TMA) and Thromboembolism Associated With HEMLIBRA and aPCC
In clinical trials, TMA was reported in 0.8% of patients (3/391) and thrombotic events were reported in 0.5% of patients (2/391). In patients who received at least one dose of aPCC, TMA was reported in 8.1% of patients (3/37) and thrombotic events were reported in 5.4% of patients (2/37). Patients with TMA presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13.
Consider the benefits and risks if aPCC must be used in a patient receiving HEMLIBRA prophylaxis. Monitor for the development of TMA and/or thromboembolism when administering aPCC. Immediately discontinue aPCC and interrupt HEMLIBRA prophylaxis if clinical symptoms, imaging, or laboratory findings consistent with TMA and/or thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of TMA and/or thrombotic events on a case-by-case basis.
Laboratory Coagulation Test Interference
HEMLIBRA affects intrinsic pathway clotting-based laboratory tests, including activated clotting time (ACT); activated partial thromboplastin time (aPTT); and all assays based on aPTT, such as one-stage, factor VIII (FVIII) activity. Therefore, intrinsic pathway clotting-based coagulation laboratory test results in patients who have been treated with HEMLIBRA prophylaxis should not be used to monitor HEMLIBRA activity, determine dosing for factor replacement or anti-coagulation, or measure FVIII inhibitor titers.
Results affected by HEMLIBRA: aPTT; Bethesda assays (clotting-based) for FVIII inhibitor titers; one-stage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC-R); ACT.
Results unaffected by HEMLIBRA: Bethesda assays (bovine chromogenic) for FVIII inhibitor titers; thrombin time (TT); one-stage, prothrombin time (PT)-based single-factor assays; chromogenic-based single-factor assays other than FVIII (see Drug Interactions for FVIII chromogenic activity assay considerations); immuno-based assays (ie, ELISA, turbidimetric methods); genetic tests of coagulation factors (eg, Factor V Leiden, Prothrombin 20210).
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
Characterization of aPCC Treatment in Pooled Clinical Trials
There were 130 instances of aPCC treatment in 37 patients, of which 13 instances (10%) consisted of on average a cumulative amount of >100 U/kg/24 hours of aPCC for 24 hours or more; 2 of the 13 were associated with thrombotic events and 3 of the 13 were associated with TMA. No TMA or thrombotic events were associated with the remaining instances of aPCC treatment.
Injection Site Reactions
In total, 85 patients (22%) reported injection site reactions (ISRs). All ISRs observed in HEMLIBRA clinical trials were reported as mild to moderate intensity and 93% resolved without treatment. The commonly reported ISR symptoms were injection site erythema (11%), injection site pruritus (4%), and injection site pain (4%).
Other Less Common (<1%) Reactions
Rhabdomyolysis was reported in 2 adult patients with asymptomatic elevations in serum creatine kinase without associated renal or musculoskeletal symptoms. In both instances, the event occurred following an increase in physical activity.
Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC.
Pregnancy, Lactation, Females and Males of Reproductive Potential
Women of childbearing potential should use contraception while receiving HEMLIBRA. It is not known whether HEMLIBRA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HEMLIBRA should be used during pregnancy only if the potential benefit for the mother outweighs the risk to the fetus. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for HEMLIBRA and any potential adverse effects on the breastfed child from HEMLIBRA or from the underlying maternal condition.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
HEMLIBRA [package insert]. South San Francisco, CA: Genentech,
FDA approves Genentech’s HEMLIBRA (emicizumab-kxwh) for hemophilia A
without factor VIII inhibitors. [press release]. South San Francisco,
CA: Genentech; October 4, 2018.
Data on file. Genentech, Inc.
ClinicalTrials.gov. A study to evaluate the efficacy, safety, and
pharmacokinetics of prophylactic emicizumab versus no prophylaxis in
hemophilia A participants with inhibitors (HAVEN 1). NCT02622321.
https://clinicaltrials.gov/ct2/show/NCT02622321. Accessed August 1,
ClinicalTrials.gov. A study of emicizumab administered subcutaneously
(SC) in pediatric participants with hemophilia A and factor VIII
(FVIII) inhibitors (HAVEN 2). NCT02795767.
https://clinicaltrials.gov/ct2/show/NCT02795767. Accessed August 1,
ClinicalTrials.gov. A clinical trial to evaluate prophylactic
emicizumab versus no prophylaxis in hemophilia A participants without
inhibitors (HAVEN 3). NCT02847637.
https://clinicaltrials.gov/ct2/show/NCT02847637. Accessed August 1,
ClinicalTrials.gov. A study to evaluate the efficacy, safety,
pharmacokinetics, and pharmacodynamics of emicizumab given every 4
weeks in participants with hemophilia A (HAVEN 4). NCT03020160.
https://clinicaltrials.gov/ct2/show/NCT03020160. Accessed August 1,
Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic
cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa,
emicizumab, depends on its ability to bridge the antigens. Thromb
Young G, Liesner R, Sidonio R Jr, et al. Emicizumab prophylaxis
provides flexible and effective bleed control in children with
hemophilia A with inhibitors: results from the HAVEN 2 study.
Presented at: ASH 60th Annual Meeting of the American Society of
Hematology; December 1–4, 2018; San Diego, CA.
Callaghan M, Negrier C, Paz-Priel I, et al. Emicizumab treatment is
efficacious and well tolerated long term in persons with haemophilia
(PwHA) with or without FVIII inhibitors: pooled data from four HAVEN
studies. Slide deck presented at: ISTH 2019 Annual Meeting; July 9,
2019; Melbourne, AU.
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in
hemophilia A with inhibitors. N Engl J Med.
Di Minno A, Spadarella G, Nardone A, et al. Attempting to remedy
sub-optimal medication adherence in haemophilia: the rationale for
repeated ultrasound visualisations of the patient’s joint status.
Blood Rev. 2019;33:106-119.
Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds
in haemophilia patients with inhibitors to factor VIII/IX. J Clin
Schrijvers LH, Schuurmans MJ, Fischer K. Promoting self-management
and adherence during prophylaxis: evidence-based recommendations for
haemophilia professionals. Haemophilia.
Manco-Johnson MM, Abshire TC, Shapiro AD, et al. Prophylaxis versus
episodic treatment to prevent joint disease in boys with severe
hemophilia. N Engl J Med. 2007;357(6):535-544.
National Hemophilia Foundation. Recommendation on the use and
management of emicizumab-kxwh (HEMLIBRA®) for hemophilia A
with and without inhibitors. December 6, 2018; New York, NY.
Young G, Liesner R, Chang TY, et al. A multicenter, open-label, phase
3 study of emicizumab prophylaxis in children with hemophilia A with
inhibitors. Blood. 2019;2019001869. doi:
Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25:979-987. https://doi.org/10.1111/hae.13848.
Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience
in two multicenter, open-label phase 3 studies of emicizumab in
persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)
[abstract]. Presented at: 59th Annual Meeting of the American Society
of Hematology; December 9–12, 2017; Atlanta, GA.
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
National Hemophilia Foundation. MASAC update on the approval and availability of the new treatment: Emicizumab (HEMLIBRA), for persons with hemophilia A with inhibitors to factor VIII: Interim guidance on acute bleed management and use of laboratory assays. November 24, 2017; New York, NY.
Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479.
Santagostino E, Parnes A, Dhalluin C, et al. Surgical procedures in
persons with haemophilia A (PwHA) without inhibitors receiving
emicizumab – experience from the HAVEN 3 study. Presented at: 12th
Annual Congress of the European Association of Haemophilia and Allied
Disorders (EAHAD); February 6–8, 2019; Prague, Czech Republic.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.